Correlate the following specific cellular and molecular biopsy findings with the targeted pharmacologic agent most appropriate for exploiting that underlying neoplastic mechanism.
- Biopsy of a breast mass in a premenopausal patient reveals invasive carcinoma with marked ERBB2 gene amplification.Trastuzumab
- Bone marrow aspirate from a patient presenting with marked leukocytosis shows myeloid cells harboring the t(9;22)(q34;q11) translocation.Imatinib
- Tissue analysis of metastatic non-small cell lung cancer in a lifelong non-smoker demonstrates an EML4-ALK inversion.Crizotinib
- Molecular profiling of recurrent high-grade serous ovarian carcinoma identifies a deleterious germline BRCA1 mutation.Olaparib
Cevap
The correct matches pair the specific foundational molecular derangement identified in the biopsy with its corresponding targeted pharmacologic inhibitor.
Each correct pair accurately links a fundamental molecular derangement within a neoplastic cell to the pharmacologic agent specifically designed to inhibit or exploit that altered pathway.
Adım Adım Çözüm
Anahtar Kavram
Targeted oncologic therapies exploit specific molecular vulnerabilities characteristic of distinct neoplastic processes, such as oncogene addiction (e.g., HER2, BCR-ABL, ALK) or synthetic lethality (e.g., PARP inhibition in BRCA-mutated cells).